ROLE OF SERUM FATTY ACID BINDING PROTEIN (FABP) AND HIGH SENSITIVE CARDIAC TROPONIN (HS-CTN) IN DIAGNOSIS AND DIFFERENTIATION OF ACUTE CORONARY SYNDROME
Bashar J. Hussein*, Basil O. Saleh and Nazar N Abbas
ABSTRACT
Background: Acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute myocardial ischemia including unstable angina, Non-ST-segment elevation myocardial infarction & ST-segment elevation myocardial infarction. Heart – type fatty acid binding protein (H-FABP) also known as mammary-derived growth inhibitor is a protein that in humans is encoded by the FABP3 gene, The diagnostic potential of the biomarker H-FABP for heart injury. Patients, Material & Methods: The present study was conducted at the Department of Biochemistry, College of Medicine/ University of Baghdad during the period from December 2017 until August 2018. Thirty three patients with ACS were included as 11 with unstable angina (UA), 11 with non ST elevation myocardial infarction (NSTEMI), & 11 ST elevation myocardial infarction (STEMI) patients. Also this study included 18 non-ischemic chest pain subjects who served as pathological control. Blood samples were obtained for measurements of FABP and hs-cTn by ELISA method. Results: The mean (±SD) value of FABP was significantly increased in NSTEMI (3.80 ± 1.45ng/ml, p< 0.001) and UA (3.62 ± 0.42 ng/ml, p < 0.001) compared to that of STEMI (1.88 ± 1.60 ng/ml). Also, the mean value of serum H-FABP levels of pathological controls (3.17 ± 0.73 ng/ml) was significantly higher than that of STEMI group (p < 0.001). Regarding hs-cTn, it did not differ significantly among the groups of UA (2.82 ± 0.69), NSTMI (4.08 ± 2.35), and STMI (4.53 ± 2.06). Conclusion: FABP showed significant elevation in UA and NSTMI and may be used as a biochemical marker in assessment of these two conditions and to differentiate them from STEMI.
Keywords: Acute Coronary Syndrome, FABP, hs-cTn.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
